Polygenic embryo screening: Four clinical considerations warrant further attention

S. Pereira*, S. Carmi, G. Altarescu, J. Austin, D. Barlevy, A. Hershlag, E. Juengst, K. Kostick-Quenet, E. Kovanci, R. B. Lathi, M. Mukherjee, I. Van Den Veyver, O. Zuk, G. Lázaro-Muñoz, T. Lencz

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

8 Scopus citations


Recent advances in developing polygenic scores have made it possible to screen embryos for common, complex conditions and traits. Polygenic embryo screening (PES) is currently offered commercially, and though there has been much recent media and academic coverage, reproductive specialists' points of view have not yet been prominent in these discussions. We convened a roundtable of multidisciplinary experts, including reproductive specialists to discuss PES and its implications. In this Opinion, we describe four clinically relevant issues associated with the use of PES that have not yet been discussed in the literature and warrant consideration.

Original languageAmerican English
Pages (from-to)1375-1378
Number of pages4
JournalHuman Reproduction
Issue number7
StatePublished - 1 Jul 2022

Bibliographical note

Publisher Copyright:
© 2022 The Author(s) 2022. Published by Oxford University Press on behalf of European Society of Human Reproduction and Embryology. All rights reserved.


  • PRS
  • embryo screening
  • genetic screening
  • genomic risk scores
  • polygenic embryo screening
  • polygenic risk scores
  • trait screening


Dive into the research topics of 'Polygenic embryo screening: Four clinical considerations warrant further attention'. Together they form a unique fingerprint.

Cite this